{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:46:01Z","timestamp":1759941961027},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":4808,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eighty\u2010eight patients with low grade non\u2010Hodgkin's lymphoma were followed for a median period of 63 months. Sixty\u2010eight per cent of the group were centrocytic\/centroblastic B cell lymphomas by the updated Kiel classification. Fifty\u2010one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 of these patients the bone marrow was the only site of extranodal involvement. Univariate survival analysis showed that the sum of involved sites was more discriminatory than Ann Arbor stage. Analysis by site of involvement showed that the liver and other intraabdominal sites were associated with worse survival than involvement of peripheral lymph nodes. Bone marrow and spleen involvement were not significantly associated with short survival. Increasing age at presentation was strongly associated with shorter survival and was also inversely correlated with serum albumin. Both low absolute lymphocyte count (&lt;1.0 \u00d7 10 <jats:sup>9<\/jats:sup>\/1), low serum IgG level (&lt;10 g\/1) and low total immunoglobulins on presentation were significantly associated with short survival. Multivariate analysis showed that age, serum albumin and number of involved sites gave the best survival prediction. The sum of involved sites, immunoglobulin level and absolute lymphocyte count may be useful objective markers of prognosis in low\u2010grade non\u2010Hodgkin's lymphoma.<\/jats:p>","DOI":"10.1002\/hon.2900120104","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T17:54:46Z","timestamp":1171907686000},"page":"15-27","source":"Crossref","is-referenced-by-count":12,"title":["Prognosis in low grade non\u2010Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level"],"prefix":"10.1002","volume":"12","author":[{"given":"D.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Alison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Child","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dovey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Farish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. R.","family":"Norfolk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"O'brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Parapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(84)90028-2"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058044"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90425-D"},{"issue":"2","key":"e_1_2_1_5_2","first-page":"123","article-title":"Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years","volume":"2","author":"Bastion Y.","year":"1991","journal-title":"Ann. Oncol."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.762"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.41.8.866"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.44.3.215"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198701083160204"},{"key":"e_1_2_1_11_2","first-page":"2271","article-title":"BCL2\/JH rearrangements in benign lymphoid tissues with follicular hyperplasia","volume":"6","author":"Limpens J.","year":"1991","journal-title":"Oncogene"},{"key":"e_1_2_1_12_2","first-page":"92","article-title":"Updated Kiel Classification for lymphomas","author":"Stansfeld A. G.","year":"1988","journal-title":"Lancet"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_1_15_2","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone P. P.","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_1_16_2","first-page":"43","article-title":"The Staging of Non\u2010Hodgkin's lymphomas","volume":"17","author":"Moormeier J. A.","year":"1990","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197906213002501"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90273-2"},{"issue":"2","key":"e_1_2_1_19_2","first-page":"99","article-title":"The significance of B clonal excess in patients with non\u2010Hodgkin's lymphoma in remission","volume":"2","author":"Johnson A.","year":"1991","journal-title":"Ann Oncol."},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood.V73.2.366.366","article-title":"Crossover study of immunoglobulin replacement therapy in patients with low\u2010grade B cell tumours","volume":"73","author":"Griffiths H.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-51-3-501"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4"},{"key":"e_1_2_1_23_2","first-page":"125","volume-title":"Protein Reference Unit Handbook of Clinical Immunochemistry","author":"Milford Ward A.","year":"1988"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900120104","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900120104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:03:46Z","timestamp":1698203026000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900120104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/hon.2900120104"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900120104","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}